Molecular biologist Daniel Wallerstorfer, CEO of Novogenia, emphasizes that individual caffeine tolerance is genetically determined. The CYP1A2 gene, also known as the caffeine gene, influences how well a person can metabolize caffeine. People with an intact caffeine gene benefit from the antioxidant properties of coffee and have a 50% lower risk of heart attack compared to non-coffee drinkers. Novogenia offers personalized dietary supplements based on individual genetic and blood analyses to optimally support health.